Investors with the goal of beating the broader market often turn to stock selection. Strategic choices in individual stocks can have a profound impact on your wealth.
After finishing at $10.95 in the prior trading day, UroGen Pharma Ltd (NASDAQ: URGN) closed at $9.69, down -11.51%. In other words, the price has decreased by -$11.51 from its previous closing price. On the day, 0.8 million shares were traded.
Ratios:
Our goal is to gain a better understanding of URGN by taking a closer look at its different ratios. For the most recent quarter (mrq), Quick Ratio is recorded 5.81 and its Current Ratio is at 6.01.
Upgrades & Downgrades
In addition, analysts’ ratings and any changes thereto give investors an idea of the stock’s future direction. In the most recent recommendation for this company, Scotiabank on April 16, 2025, initiated with a Sector Outperform rating and assigned the stock a target price of $23.
On August 22, 2024, Guggenheim started tracking the stock assigning a Buy rating and target price of $40.Guggenheim initiated its Buy rating on August 22, 2024, with a $40 target price.
Insider Transactions:
The insider trade also gives investors a glimpse into the future direction of stock prices, which can be beneficial to investors. A recent insider transaction in this stock occurred on Jan 31 ’25 when Schoenberg Mark sold 4,551 shares for $11.14 per share. The transaction valued at 50,698 led to the insider holds 145,666 shares of the business.
Smith Jason Drew sold 7,379 shares of URGN for $82,202 on Jan 31 ’25. The General Counsel now owns 26,468 shares after completing the transaction at $11.14 per share. On Sep 09 ’24, another insider, Schoenberg Mark, who serves as the Chief Medical Officer of the company, sold 859 shares for $13.08 each. As a result, the insider received 11,236 and left with 145,091 shares of the company.
Valuation Measures:
For the stock, the TTM Price-to-Sale (P/S) ratio is 4.94.
Stock Price History:
Over the past 52 weeks, URGN has reached a high of $20.70, while it has fallen to a 52-week low of $8.94. The 50-Day Moving Average of the stock is -8.22%, while the 200-Day Moving Average is calculated to be -19.32%.
Shares Statistics:
A total of 42.23M shares are outstanding, with a floating share count of 38.23M. Insiders hold about 17.09% of the company’s shares, while institutions hold 80.39% stake in the company.
Earnings Estimates
The market rating of UroGen Pharma Ltd (URGN) is currently shaped by the ongoing analysis conducted by 6.0 analysts closely monitoring its performance.The consensus estimate for the next quarter is -$0.79, with high estimates of -$0.42 and low estimates of -$1.0.
Analysts are recommending an EPS of between -$1.71 and -$3.71 for the fiscal current year, implying an average EPS of -$2.88. EPS for the following year is -$0.52, with 5.0 analysts recommending between $2.04 and -$2.4.
Revenue Estimates
7 analysts predict $22.7M in revenue for the current quarter. It ranges from a high estimate of $29.53M to a low estimate of $20.14M. As of the current estimate, UroGen Pharma Ltd’s year-ago sales were $18.78MFor the next quarter, 7 analysts are estimating revenue of $24.66M. There is a high estimate of $30.76M for the next quarter, whereas the lowest estimate is $22.77M.
A total of 7 analysts have provided revenue estimates for URGN’s current fiscal year. The highest revenue estimate was $137.5M, while the lowest revenue estimate was $111.19M, resulting in an average revenue estimate of $121.69M. In the same quarter a year ago, actual revenue was $90.4MBased on 7 analysts’ estimates, the company’s revenue will be $264.55M in the next fiscal year. The high estimate is $391.48M and the low estimate is $187.35M.
